Will biosimilars burst into a $36B U.S. market?

It is easy to create generics from conventional drugs, but not so for biologics, which involve active biological ingredients such as proteins that can be leveraged to treat cancer and a range of other diseases. Biosimilars, which mimic biologics as closely as possible, could be the next big thing in the U.S., but a hot debate has been pitched over what to name these drugs.

In foreign markets biologics are already being made into biosimilars, which are the closest thing to generic form that these drugs can get. This Washington Post piece unpacks the possibility of biologics in America and the implications of this name game within the industry.